MEMSID: Results From a Phase 2 Pilot Study on Memantine Treatment for Sickle Cell Disease
Hemasphere
.
2020 Aug 11;4(4):e452.
doi: 10.1097/HS9.0000000000000452.
eCollection 2020 Aug.
Authors
Inga Hegemann
1
,
Clelia Sasselli
1
,
Fabio Valeri
2
,
Asya Makhro
3
4
,
Rouven Müller
1
,
Anna Bogdanova
3
4
,
Markus G Manz
1
,
Max Gassmann
3
4
,
Jeroen S Goede
1
4
5
Affiliations
1
Department of Medical Oncology and Hematology, University Hospital and University of Zurich, Zurich, Switzerland.
2
Institute of Primary Care, University of Zurich, Zurich, Switzerland.
3
Institute of Veterinary Physiology, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland.
4
Zurich Center for Integrative Human Physiology (ZIHP), University of Zurich, Zurich, Switzerland.
5
Division of Oncology and Hematology, Kantonsspital Winterthur, Winterthur, Switzerland.
PMID:
32885144
PMCID:
PMC7430229
DOI:
10.1097/HS9.0000000000000452
No abstract available